UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
| | | | | |
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2022March 31, 2023
OR
| | | | | |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File No. 1-2189
ABBOTT LABORATORIES
| | | | | |
An Illinois Corporation | I.R.S. Employer Identification No. |
| 36-0698440 |
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
| | | | | | | | |
| | |
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
Common Shares, Without Par Value | ABT | New York Stock Exchange Chicago Stock Exchange, Inc. |
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | |
Large Accelerated Filer x | Accelerated Filer o |
| |
Non-Accelerated Filer o | Smaller reporting company o |
| |
| Emerging growth company o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of September 30, 2022,March 31, 2023, Abbott Laboratories had 1,743,573,7771,738,946,799 common shares without par value outstanding.
Abbott Laboratories
Table of Contents
Abbott Laboratories and Subsidiaries
CondensedCondensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
| | | Three Months Ended | | Nine Months Ended | | Three Months Ended |
| | September 30 | | September 30 | | March 31 |
| | 2022 | | 2021 | | 2022 | | 2021 | | 2023 | | 2022 |
Net sales | Net sales | $ | 10,410 | | | $ | 10,928 | | | $ | 33,562 | | | $ | 31,607 | | Net sales | $ | 9,747 | | | $ | 11,895 | |
| Cost of products sold, excluding amortization of intangible assets | Cost of products sold, excluding amortization of intangible assets | 4,629 | | | 4,423 | | | 14,549 | | | 13,771 | | Cost of products sold, excluding amortization of intangible assets | 4,331 | | | 4,987 | |
Amortization of intangible assets | Amortization of intangible assets | 498 | | | 520 | | | 1,517 | | | 1,533 | | Amortization of intangible assets | 491 | | | 512 | |
Research and development | Research and development | 782 | | | 672 | | | 2,163 | | | 1,980 | | Research and development | 654 | | | 697 | |
Selling, general and administrative | Selling, general and administrative | 2,731 | | | 2,767 | | | 8,275 | | | 8,276 | | Selling, general and administrative | 2,762 | | | 2,787 | |
Total operating cost and expenses | Total operating cost and expenses | 8,640 | | | 8,382 | | | 26,504 | | | 25,560 | | Total operating cost and expenses | 8,238 | | | 8,983 | |
| Operating earnings | Operating earnings | 1,770 | | | 2,546 | | | 7,058 | | | 6,047 | | Operating earnings | 1,509 | | | 2,912 | |
| Interest expense | Interest expense | 141 | | | 133 | | | 404 | | | 402 | | Interest expense | 153 | | | 131 | |
Interest (income) | Interest (income) | (55) | | | (10) | | | (95) | | | (32) | | Interest (income) | (101) | | | (14) | |
Net foreign exchange (gain) loss | Net foreign exchange (gain) loss | 19 | | | 4 | | | 16 | | | 7 | | Net foreign exchange (gain) loss | 6 | | | (3) | |
Other (income) expense, net | Other (income) expense, net | (93) | | | (74) | | | (253) | | | (214) | | Other (income) expense, net | (111) | | | (78) | |
Earnings before taxes | Earnings before taxes | 1,758 | | | 2,493 | | | 6,986 | | | 5,884 | | Earnings before taxes | 1,562 | | | 2,876 | |
Taxes on earnings | Taxes on earnings | 323 | | | 393 | | | 1,086 | | | 802 | | Taxes on earnings | 244 | | | 429 | |
Net Earnings | Net Earnings | $ | 1,435 | | | $ | 2,100 | | | $ | 5,900 | | | $ | 5,082 | | Net Earnings | $ | 1,318 | | | $ | 2,447 | |
| Basic Earnings Per Common Share | Basic Earnings Per Common Share | $ | 0.82 | | | $ | 1.18 | | | $ | 3.35 | | | $ | 2.85 | | Basic Earnings Per Common Share | $ | 0.75 | | | $ | 1.38 | |
| Diluted Earnings Per Common Share | Diluted Earnings Per Common Share | $ | 0.81 | | | $ | 1.17 | | | $ | 3.32 | | | $ | 2.83 | | Diluted Earnings Per Common Share | $ | 0.75 | | | $ | 1.37 | |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share | Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share | 1,752,968 | | | 1,774,516 | | | 1,756,209 | | | 1,776,870 | | Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share | 1,741,738 | | | 1,761,911 | |
Dilutive Common Stock Options | Dilutive Common Stock Options | 10,685 | | | 14,483 | | | 11,638 | | | 14,407 | | Dilutive Common Stock Options | 9,977 | | | 12,631 | |
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,763,653 | | | 1,788,999 | | | 1,767,847 | | | 1,791,277 | | Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,751,715 | | | 1,774,542 | |
| Outstanding Common Stock Options Having No Dilutive Effect | Outstanding Common Stock Options Having No Dilutive Effect | 5,445 | | | 2,740 | | | 2,655 | | | 2,694 | | Outstanding Common Stock Options Having No Dilutive Effect | 7,332 | | | 2,655 | |
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)(Unaudited)
(dollars in millions)millions)
| | | Three Months Ended | | Nine Months Ended | | Three Months Ended |
| | September 30 | | September 30 | | March 31 |
| | 2022 | | 2021 | | 2022 | | 2021 | | 2023 | | 2022 |
Net Earnings | Net Earnings | $ | 1,435 | | | $ | 2,100 | | | $ | 5,900 | | | $ | 5,082 | | Net Earnings | $ | 1,318 | | | $ | 2,447 | |
Foreign currency translation gain (loss) adjustments | Foreign currency translation gain (loss) adjustments | (1,008) | | | (391) | | | (1,429) | | | (762) | | Foreign currency translation gain (loss) adjustments | 139 | | | (106) | |
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54 in 2021 | 56 | | | 78 | | | 172 | | | 211 | | |
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021 | 213 | | | 139 | | | 186 | | | 257 | | |
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $— in 2023 and $13 in 2022 | | Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $— in 2023 and $13 in 2022 | 2 | | | 62 | |
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $(58) in 2023 and $(15) in 2022 | | Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $(58) in 2023 and $(15) in 2022 | (129) | | | (56) | |
Other comprehensive income (loss) | Other comprehensive income (loss) | (739) | | | (174) | | | (1,071) | | | (294) | | Other comprehensive income (loss) | 12 | | | (100) | |
Comprehensive Income | Comprehensive Income | $ | 696 | | | $ | 1,926 | | | $ | 4,829 | | | $ | 4,788 | | Comprehensive Income | $ | 1,330 | | | $ | 2,347 | |
| | | September 30, 2022 | | December 31, 2021 | | March 31, 2023 | | December 31, 2022 |
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: | Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: | | | | Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: | | | |
Cumulative foreign currency translation (loss) adjustments | Cumulative foreign currency translation (loss) adjustments | $ | (7,268) | | | $ | (5,839) | | Cumulative foreign currency translation (loss) adjustments | $ | (6,594) | | | $ | (6,733) | |
Net actuarial (losses) and prior service (costs) and credits | Net actuarial (losses) and prior service (costs) and credits | (2,498) | | | (2,670) | | Net actuarial (losses) and prior service (costs) and credits | (1,491) | | | (1,493) | |
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other | 321 | | | 135 | | |
Accumulated other comprehensive income (loss) | $ | (9,445) | | | $ | (8,374) | | |
Cumulative gains (losses) on derivative instruments designated as cash flow hedges | | Cumulative gains (losses) on derivative instruments designated as cash flow hedges | 46 | | | 175 | |
Accumulated Other Comprehensive Income (Loss) | | Accumulated Other Comprehensive Income (Loss) | $ | (8,039) | | | $ | (8,051) | |
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)
| | | September 30, 2022 | | December 31, 2021 | | March 31, 2023 | | December 31, 2022 |
Assets | Assets | | | | Assets | | | |
Current Assets: | Current Assets: | | Current Assets: | |
Cash and cash equivalents | Cash and cash equivalents | $ | 9,594 | | | $ | 9,799 | | Cash and cash equivalents | $ | 9,161 | | | $ | 9,882 | |
Short-term investments | Short-term investments | 313 | | | 450 | | Short-term investments | 371 | | | 288 | |
Trade receivables, less allowances of $520 in 2022 and $519 in 2021 | 6,408 | | | 6,487 | | |
Trade receivables, less allowances of $503 in 2023 and $500 in 2022 | | Trade receivables, less allowances of $503 in 2023 and $500 in 2022 | 6,020 | | | 6,218 | |
Inventories: | Inventories: | | Inventories: | |
Finished products | Finished products | 3,407 | | | 3,081 | | Finished products | 3,944 | | | 3,805 | |
Work in process | Work in process | 726 | | | 694 | | Work in process | 805 | | | 680 | |
Materials | Materials | 1,601 | | | 1,382 | | Materials | 1,924 | | | 1,688 | |
Total inventories | Total inventories | 5,734 | | | 5,157 | | Total inventories | 6,673 | | | 6,173 | |
Prepaid expenses and other receivables | Prepaid expenses and other receivables | 2,796 | | | 2,346 | | Prepaid expenses and other receivables | 2,152 | | | 2,663 | |
Total Current Assets | Total Current Assets | 24,845 | | | 24,239 | | Total Current Assets | 24,377 | | | 25,224 | |
Investments | Investments | 764 | | | 816 | | Investments | 776 | | | 766 | |
Property and equipment, at cost | Property and equipment, at cost | 19,306 | | | 19,364 | | Property and equipment, at cost | 20,605 | | | 20,212 | |
Less: accumulated depreciation and amortization | Less: accumulated depreciation and amortization | 10,617 | | | 10,405 | | Less: accumulated depreciation and amortization | 11,323 | | | 11,050 | |
Net property and equipment | Net property and equipment | 8,689 | | | 8,959 | | Net property and equipment | 9,282 | | | 9,162 | |
Intangible assets, net of amortization | Intangible assets, net of amortization | 10,850 | | | 12,739 | | Intangible assets, net of amortization | 10,006 | | | 10,454 | |
Goodwill | Goodwill | 22,284 | | | 23,231 | | Goodwill | 22,927 | | | 22,799 | |
Deferred income taxes and other assets | Deferred income taxes and other assets | 5,369 | | | 5,212 | | Deferred income taxes and other assets | 6,426 | | | 6,033 | |
| | $ | 72,801 | | | $ | 75,196 | | | $ | 73,794 | | | $ | 74,438 | |
Liabilities and Shareholders’ Investment | Liabilities and Shareholders’ Investment | | | | Liabilities and Shareholders’ Investment | | | |
Current Liabilities: | Current Liabilities: | | Current Liabilities: | |
Trade accounts payable | Trade accounts payable | $ | 4,133 | | | $ | 4,408 | | Trade accounts payable | $ | 4,167 | | | $ | 4,607 | |
Salaries, wages and commissions | Salaries, wages and commissions | 1,426 | | | 1,625 | | Salaries, wages and commissions | 1,098 | | | 1,556 | |
Other accrued liabilities | Other accrued liabilities | 5,475 | | | 5,181 | | Other accrued liabilities | 5,758 | | | 5,845 | |
Dividends payable | Dividends payable | 820 | | | 831 | | Dividends payable | 888 | | | 887 | |
Income taxes payable | Income taxes payable | 394 | | | 306 | | Income taxes payable | 334 | | | 343 | |
Current portion of long-term debt | Current portion of long-term debt | 1,117 | | | 754 | | Current portion of long-term debt | 2,285 | | | 2,251 | |
Total Current Liabilities | Total Current Liabilities | 13,365 | | | 13,105 | | Total Current Liabilities | 14,530 | | | 15,489 | |
Long-term debt | Long-term debt | 15,297 | | | 17,296 | | Long-term debt | 14,615 | | | 14,522 | |
Post-employment obligations, deferred income taxes and other long-term liabilities | Post-employment obligations, deferred income taxes and other long-term liabilities | 8,255 | | | 8,771 | | Post-employment obligations, deferred income taxes and other long-term liabilities | 7,417 | | | 7,522 | |
Commitments and Contingencies | Commitments and Contingencies | | Commitments and Contingencies | |
Shareholders’ Investment: | Shareholders’ Investment: | | Shareholders’ Investment: | |
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued | Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued | — | | | — | | Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued | — | | | — | |
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2022: 1,985,919,440; 2021: 1,985,273,421 | 24,560 | | | 24,470 | | |
Common shares held in treasury, at cost — Shares: 2022: 242,345,663; 2021: 221,191,228 | (14,555) | | | (11,822) | | |
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,986,904,170; 2022: 1,986,519,278 | | Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,986,904,170; 2022: 1,986,519,278 | 24,488 | | | 24,709 | |
Common shares held in treasury, at cost — Shares: 2023: 247,957,371; 2022: 248,724,257 | | Common shares held in treasury, at cost — Shares: 2023: 247,957,371; 2022: 248,724,257 | (15,307) | | | (15,229) | |
Earnings employed in the business | Earnings employed in the business | 35,115 | | | 31,528 | | Earnings employed in the business | 35,868 | | | 35,257 | |
Accumulated other comprehensive income (loss) | Accumulated other comprehensive income (loss) | (9,445) | | | (8,374) | | Accumulated other comprehensive income (loss) | (8,039) | | | (8,051) | |
Total Abbott Shareholders’ Investment | Total Abbott Shareholders’ Investment | 35,675 | | | 35,802 | | Total Abbott Shareholders’ Investment | 37,010 | | | 36,686 | |
Noncontrolling Interests in Subsidiaries | Noncontrolling Interests in Subsidiaries | 209 | | | 222 | | Noncontrolling Interests in Subsidiaries | 222 | | | 219 | |
Total Shareholders’ Investment | Total Shareholders’ Investment | 35,884 | | | 36,024 | | Total Shareholders’ Investment | 37,232 | | | 36,905 | |
| | $ | 72,801 | | | $ | 75,196 | | | $ | 73,794 | | | $ | 74,438 | |
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
| | | | | | | | | | | |
| Three Months Ended September 30 |
| 2022 | | 2021 |
Common Shares: | | | |
Balance at June 30 | | | |
Shares: 2022: 1,985,676,735; 2021: 1,982,553,488 | $ | 24,429 | | | $ | 24,153 | |
Issued under incentive stock programs | | | |
Shares: 2022: 242,705; 2021: 550,366 | 12 | | | 26 | |
Share-based compensation | 123 | | | 113 | |
Issuance of restricted stock awards | (4) | | | (7) | |
Balance at September 30 | | | |
Shares: 2022: 1,985,919,440; 2021: 1,983,103,854 | $ | 24,560 | | | $ | 24,285 | |
| | | |
Common Shares Held in Treasury: | | | |
Balance at June 30 | | | |
Shares: 2022: 234,456,992; 2021: 209,736,139 | $ | (13,720) | | | $ | (10,340) | |
Issued under incentive stock programs | | | |
Shares: 2022: 528,436; 2021: 545,860 | 31 | | | 26 | |
Purchased | | | |
Shares: 2022: 8,417,107; 2021: 5,626,606 | (866) | | | (685) | |
Balance at September 30 | | | |
Shares: 2022: 242,345,663; 2021: 214,816,885 | $ | (14,555) | | | $ | (10,999) | |
| | | |
Earnings Employed in the Business: | | | |
Balance at June 30 | $ | 34,487 | | | $ | 29,053 | |
Net earnings | 1,435 | | | 2,100 | |
Cash dividends declared on common shares (per share — 2022: $0.47; 2021: $0.45) | (822) | | | (799) | |
Effect of common and treasury share transactions | 15 | | | 22 | |
Balance at September 30 | $ | 35,115 | | | $ | 30,376 | |
| | | |
Accumulated Other Comprehensive Income (Loss): | | | |
Balance at June 30 | $ | (8,706) | | | $ | (9,066) | |
Other comprehensive income (loss) | (739) | | | (174) | |
Balance at September 30 | $ | (9,445) | | | $ | (9,240) | |
| | | |
Noncontrolling Interests in Subsidiaries: | | | |
Balance at June 30 | $ | 226 | | | $ | 229 | |
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases | (17) | | | (13) | |
Balance at September 30 | $ | 209 | | | $ | 216 | |
The accompanying notes to condensed consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
| | | Nine Months Ended September 30 | | Three Months Ended March 31 |
| | 2022 | | 2021 | | 2023 | | 2022 |
Common Shares: | Common Shares: | | | | Common Shares: | | | |
Balance at January 1 | Balance at January 1 | | Balance at January 1 | |
Shares: 2022: 1,985,273,421; 2021: 1,981,156,896 | $ | 24,470 | | | $ | 24,145 | | |
Shares: 2023: 1,986,519,278; 2022: 1,985,273,421 | | Shares: 2023: 1,986,519,278; 2022: 1,985,273,421 | $ | 24,709 | | | $ | 24,470 | |
Issued under incentive stock programs | Issued under incentive stock programs | | Issued under incentive stock programs | | | |
Shares: 2022: 646,019; 2021: 1,946,958 | 36 | | | 91 | | |
Shares: 2023: 384,892; 2022: 251,632 | | Shares: 2023: 384,892; 2022: 251,632 | 16 | | | 14 | |
Share-based compensation | Share-based compensation | 572 | | | 536 | | Share-based compensation | 296 | | | 324 | |
Issuance of restricted stock awards | Issuance of restricted stock awards | (518) | | | (487) | | Issuance of restricted stock awards | (533) | | | (504) | |
Balance at September 30 | | | | |
Shares: 2022: 1,985,919,440; 2021: 1,983,103,854 | $ | 24,560 | | | $ | 24,285 | | |
Balance at March 31 | | Balance at March 31 | | | |
Shares: 2023: 1,986,904,170; 2022: 1,985,525,053 | | Shares: 2023: 1,986,904,170; 2022: 1,985,525,053 | $ | 24,488 | | | $ | 24,304 | |
| Common Shares Held in Treasury: | Common Shares Held in Treasury: | | Common Shares Held in Treasury: | |
Balance at January 1 | Balance at January 1 | | Balance at January 1 | |
Shares: 2022: 221,191,228; 2021: 209,926,622 | $ | (11,822) | | | $ | (10,042) | | |
Shares: 2023: 248,724,257; 2022: 221,191,228 | | Shares: 2023: 248,724,257; 2022: 221,191,228 | $ | (15,229) | | | $ | (11,822) | |
Issued under incentive stock programs | Issued under incentive stock programs | | Issued under incentive stock programs | | | |
Shares: 2022: 4,808,575; 2021: 5,524,291 | 261 | | | 265 | | |
Shares: 2023: 3,933,165; 2022: 4,144,476 | | Shares: 2023: 3,933,165; 2022: 4,144,476 | 242 | | | 223 | |
Purchased | Purchased | | Purchased | | | |
Shares: 2022: 25,963,010; 2021: 10,414,554 | (2,994) | | | (1,222) | | |
Balance at September 30 | | | | |
Shares: 2022: 242,345,663; 2021: 214,816,885 | $ | (14,555) | | | $ | (10,999) | | |
Shares: 2023: 3,166,279; 2022: 17,536,012 | | Shares: 2023: 3,166,279; 2022: 17,536,012 | (320) | | | (2,127) | |
Balance at March 31 | | Balance at March 31 | | | |
Shares: 2023: 247,957,371; 2022: 234,582,764 | | Shares: 2023: 247,957,371; 2022: 234,582,764 | $ | (15,307) | | | $ | (13,726) | |
| Earnings Employed in the Business: | Earnings Employed in the Business: | | Earnings Employed in the Business: | |
Balance at January 1 | Balance at January 1 | $ | 31,528 | | | $ | 27,627 | | Balance at January 1 | $ | 35,257 | | | $ | 31,528 | |
Net earnings | Net earnings | 5,900 | | | 5,082 | | Net earnings | 1,318 | | | 2,447 | |
Cash dividends declared on common shares (per share — 2022: $1.41; 2021: $1.35) | (2,475) | | | (2,403) | | |
Cash dividends declared on common shares (per share — 2023: $0.51; 2022: $0.47) | | Cash dividends declared on common shares (per share — 2023: $0.51; 2022: $0.47) | (890) | | | (826) | |
Effect of common and treasury share transactions | Effect of common and treasury share transactions | 162 | | | 70 | | Effect of common and treasury share transactions | 183 | | | 146 | |
Balance at September 30 | $ | 35,115 | | | $ | 30,376 | | |
Balance at March 31 | | Balance at March 31 | $ | 35,868 | | | $ | 33,295 | |
| Accumulated Other Comprehensive Income (Loss): | Accumulated Other Comprehensive Income (Loss): | | Accumulated Other Comprehensive Income (Loss): | |
Balance at January 1 | Balance at January 1 | $ | (8,374) | | | $ | (8,946) | | Balance at January 1 | $ | (8,051) | | | $ | (8,374) | |
Other comprehensive income (loss) | Other comprehensive income (loss) | (1,071) | | | (294) | | Other comprehensive income (loss) | 12 | | | (100) | |
Balance at September 30 | $ | (9,445) | | | $ | (9,240) | | |
Balance at March 31 | | Balance at March 31 | $ | (8,039) | | | $ | (8,474) | |
| Noncontrolling Interests in Subsidiaries: | Noncontrolling Interests in Subsidiaries: | | Noncontrolling Interests in Subsidiaries: | |
Balance at January 1 | Balance at January 1 | $ | 222 | | | $ | 219 | | Balance at January 1 | $ | 219 | | | $ | 222 | |
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases | Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases | (13) | | | (3) | | Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases | 3 | | | 8 | |
Balance at September 30 | $ | 209 | | | $ | 216 | | |
Balance at March 31 | | Balance at March 31 | $ | 222 | | | $ | 230 | |
The accompanying notes to condensed consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
| | | | | | | | | | | |
| Three Months Ended March 31 |
| 2023 | | 2022 |
Cash Flow From (Used in) Operating Activities: | | | |
Net earnings | $ | 1,318 | | | $ | 2,447 | |
Adjustments to reconcile net earnings to net cash from operating activities — | | | |
Depreciation | 315 | | | 311 | |
Amortization of intangible assets | 491 | | | 512 | |
Share-based compensation | 281 | | | 305 | |
Trade receivables | 233 | | | (751) | |
Inventories | (419) | | | (554) | |
Other, net | (1,076) | | | (205) | |
Net Cash From Operating Activities | 1,143 | | | 2,065 | |
| | | |
Cash Flow From (Used in) Investing Activities: | | | |
Acquisitions of property and equipment | (380) | | | (321) | |
| | | |
| | | |
Sales (purchases) of other investment securities, net | (86) | | | (41) | |
Other | 4 | | | 2 | |
Net Cash From (Used in) Investing Activities | (462) | | | (360) | |
| | | |
Cash Flow From (Used in) Financing Activities: | | | |
Net borrowings (repayments) of short-term debt and other | (42) | | | 8 | |
| | | |
Repayments of long-term debt | — | | | (751) | |
Purchases of common shares | (540) | | | (2,307) | |
Proceeds from stock options exercised | 62 | | | 59 | |
Dividends paid | (890) | | | (832) | |
Net Cash From (Used in) Financing Activities | (1,410) | | | (3,823) | |
| | | |
Effect of exchange rate changes on cash and cash equivalents | 8 | | | (6) | |
| | | |
Net Increase (Decrease) in Cash and Cash Equivalents | (721) | | | (2,124) | |
Cash and Cash Equivalents, Beginning of Year | 9,882 | | | 9,799 | |
Cash and Cash Equivalents, End of Period | $ | 9,161 | | | $ | 7,675 | |
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
| | | | | | | | | | | |
| Nine Months Ended September 30 |
| 2022 | | 2021 |
Cash Flow From (Used in) Operating Activities: | | | |
Net earnings | $ | 5,900 | | | $ | 5,082 | |
Adjustments to reconcile net earnings to net cash from operating activities — | | | |
Depreciation | 943 | | | 1,122 | |
Amortization of intangible assets | 1,517 | | | 1,533 | |
Share-based compensation | 570 | | | 534 | |
Trade receivables | (409) | | | (194) | |
Inventories | (1,224) | | | (471) | |
Other, net | (42) | | | (140) | |
Net Cash From Operating Activities | 7,255 | | | 7,466 | |
| | | |
Cash Flow From (Used in) Investing Activities: | | | |
Acquisitions of property and equipment | (1,167) | | | (1,271) | |
Acquisitions of businesses and technologies, net of cash acquired | — | | | (187) | |
Proceeds from business dispositions | 48 | | | 134 | |
Sales (purchases) of other investment securities, net | (3) | | | (27) | |
Other | 14 | | | 14 | |
Net Cash From (Used in) Investing Activities | (1,108) | | | (1,337) | |
| | | |
Cash Flow From (Used in) Financing Activities: | | | |
Net borrowings (repayments) of short-term debt and other | 37 | | | (7) | |
Proceeds from issuance of long-term debt | 7 | | | — | |
Repayments of long-term debt | (753) | | | (45) | |
Purchases of common shares | (3,110) | | | (1,325) | |
Proceeds from stock options exercised | 126 | | | 173 | |
Dividends paid | (2,486) | | | (2,404) | |
Net Cash From (Used in) Financing Activities | (6,179) | | | (3,608) | |
| | | |
Effect of exchange rate changes on cash and cash equivalents | (173) | | | (57) | |
| | | |
Net Increase (Decrease) in Cash and Cash Equivalents | (205) | | | 2,464 | |
Cash and Cash Equivalents, Beginning of Year | 9,799 | | | 6,838 | |
Cash and Cash Equivalents, End of Period | $ | 9,594 | | | $ | 9,302 | |
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022March 31, 2023
(Unaudited)
Note 1 — Basis of Presentation
The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2021.2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.
Note 2 — New Accounting Standards
Recent Adopted Accounting Standards
In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 23 — Revenue
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The following tables provide detail by sales category:
| | | Three Months Ended September 30, 2022 | | Three Months Ended September 30, 2021 | | Three Months Ended March 31, 2023 | | Three Months Ended March 31, 2022 |
(in millions) | (in millions) | | U.S. | | Int’l | | Total | | U.S. | | Int’l | | Total | (in millions) | | U.S. | | Int’l | | Total | | U.S. | | Int’l | | Total |
Established Pharmaceutical Products — | Established Pharmaceutical Products — | | | | | | | | | | | | | Established Pharmaceutical Products — | | | | | | | | | | | | |
Key Emerging Markets | Key Emerging Markets | | $ | — | | | $ | 993 | | | $ | 993 | | | $ | — | | | $ | 936 | | | $ | 936 | | Key Emerging Markets | | $ | — | | | $ | 912 | | | $ | 912 | | | $ | — | | | $ | 906 | | | $ | 906 | |
Other | Other | | — | | | 333 | | | 333 | | | — | | | 329 | | | 329 | | Other | | — | | | 277 | | | 277 | | | — | | | 241 | | | 241 | |
Total | Total | | — | | | 1,326 | | | 1,326 | | | — | | | 1,265 | | | 1,265 | | Total | | — | | | 1,189 | | | 1,189 | | | — | | | 1,147 | | | 1,147 | |
Nutritionals — | Nutritionals — | | | | | | | | | | Nutritionals — | | | | | | | | | |
Pediatric Nutritionals | Pediatric Nutritionals | | 357 | | | 470 | | | 827 | | | 586 | | | 514 | | | 1,100 | | Pediatric Nutritionals | | 459 | | | 465 | | | 924 | | | 338 | | | 509 | | | 847 | |
Adult Nutritionals | Adult Nutritionals | | 329 | | | 639 | | | 968 | | | 333 | | | 675 | | | 1,008 | | Adult Nutritionals | | 353 | | | 690 | | | 1,043 | | | 339 | | | 708 | | | 1,047 | |
Total | Total | | 686 | | | 1,109 | | | 1,795 | | | 919 | | | 1,189 | | | 2,108 | | Total | | 812 | | | 1,155 | | | 1,967 | | | 677 | | | 1,217 | | | 1,894 | |
Diagnostics — | Diagnostics — | | | | | | | | | | Diagnostics — | | | | | | | | | |
Core Laboratory | Core Laboratory | | 281 | | | 938 | | | 1,219 | | | 291 | | | 1,001 | | | 1,292 | | Core Laboratory | | 289 | | | 893 | | | 1,182 | | | 268 | | | 916 | | | 1,184 | |
Molecular | Molecular | | 65 | | | 118 | | | 183 | | | 162 | | | 183 | | | 345 | | Molecular | | 47 | | | 100 | | | 147 | | | 172 | | | 248 | | | 420 | |
Point of Care | Point of Care | | 92 | | | 35 | | | 127 | | | 100 | | | 35 | | | 135 | | Point of Care | | 93 | | | 41 | | | 134 | | | 91 | | | 37 | | | 128 | |
Rapid Diagnostics | Rapid Diagnostics | | 1,303 | | | 839 | | | 2,142 | | | 1,394 | | | 746 | | | 2,140 | | Rapid Diagnostics | | 906 | | | 319 | | | 1,225 | | | 2,181 | | | 1,344 | | | 3,525 | |
Total | Total | | 1,741 | | | 1,930 | | | 3,671 | | | 1,947 | | | 1,965 | | | 3,912 | | Total | | 1,335 | | | 1,353 | | | 2,688 | | | 2,712 | | | 2,545 | | | 5,257 | |
Medical Devices — | Medical Devices — | | | | | | | | | | Medical Devices — | | | | | | | | | |
Rhythm Management | Rhythm Management | | 263 | | | 270 | | | 533 | | | 266 | | | 305 | | | 571 | | Rhythm Management | | 260 | | | 267 | | | 527 | | | 248 | | | 276 | | | 524 | |
Electrophysiology | Electrophysiology | | 225 | | | 244 | | | 469 | | | 192 | | | 293 | | | 485 | | Electrophysiology | | 238 | | | 267 | | | 505 | | | 216 | | | 269 | | | 485 | |
Heart Failure | Heart Failure | | 177 | | | 51 | | | 228 | | | 170 | | | 59 | | | 229 | | Heart Failure | | 218 | | | 63 | | | 281 | | | 196 | | | 54 | | | 250 | |
Vascular | Vascular | | 213 | | | 393 | | | 606 | | | 219 | | | 425 | | | 644 | | Vascular | | 218 | | | 399 | | | 617 | | | 209 | | | 410 | | | 619 | |
Structural Heart | Structural Heart | | 207 | | | 213 | | | 420 | | | 177 | | | 215 | | | 392 | | Structural Heart | | 210 | | | 251 | | | 461 | | | 190 | | | 221 | | | 411 | |
Neuromodulation | Neuromodulation | | 156 | | | 36 | | | 192 | | | 149 | | | 41 | | | 190 | | Neuromodulation | | 155 | | | 41 | | | 196 | | | 143 | | | 36 | | | 179 | |
Diabetes Care | Diabetes Care | | 423 | | | 744 | | | 1,167 | | | 323 | | | 798 | | | 1,121 | | Diabetes Care | | 479 | | | 834 | | | 1,313 | | | 343 | | | 783 | | | 1,126 | |
Total | Total | | 1,664 | | | 1,951 | | | 3,615 | | | 1,496 | | | 2,136 | | | 3,632 | | Total | | 1,778 | | | 2,122 | | | 3,900 | | | 1,545 | | | 2,049 | | | 3,594 | |
| Other | Other | | 3 | | | — | | | 3 | | | 6 | | | 5 | | | 11 | | Other | | 3 | | | — | | | 3 | | | 3 | | | — | | | 3 | |
| Total | Total | | $ | 4,094 | | | $ | 6,316 | | | $ | 10,410 | | | $ | 4,368 | | | $ | 6,560 | | | $ | 10,928 | | Total | | $ | 3,928 | | | $ | 5,819 | | | $ | 9,747 | | | $ | 4,937 | | | $ | 6,958 | | | $ | 11,895 | |
Abbott Laboratories and SubsidiariesNote: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Rapid Diagnostics to Heart Failure.
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 2 — Revenue (Continued)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Nine Months Ended September 30, 2022 | | Nine Months Ended September 30, 2021 |
(in millions) | | U.S. | | Int’l | | Total | | U.S. | | Int’l | | Total |
Established Pharmaceutical Products — | | | | | | | | | | | | |
Key Emerging Markets | | $ | — | | | $ | 2,826 | | | $ | 2,826 | | | $ | — | | | $ | 2,672 | | | $ | 2,672 | |
Other | | — | | | 870 | | | 870 | | | — | | | 843 | | | 843 | |
Total | | — | | | 3,696 | | | 3,696 | | | — | | | 3,515 | | | 3,515 | |
Nutritionals — | | | | | | | | | | | | |
Pediatric Nutritionals | | 1,108 | | | 1,491 | | | 2,599 | | | 1,622 | | | 1,637 | | | 3,259 | |
Adult Nutritionals | | 1,016 | | | 2,027 | | | 3,043 | | | 1,006 | | | 1,987 | | | 2,993 | |
Total | | 2,124 | | | 3,518 | | | 5,642 | | | 2,628 | | | 3,624 | | | 6,252 | |
Diagnostics — | | | | | | | | | | | | |
Core Laboratory | | 836 | | | 2,788 | | | 3,624 | | | 845 | | | 2,935 | | | 3,780 | |
Molecular | | 308 | | | 507 | | | 815 | | | 431 | | | 651 | | | 1,082 | |
Point of Care | | 284 | | | 110 | | | 394 | | | 289 | | | 112 | | | 401 | |
Rapid Diagnostics | | 5,523 | | | 2,923 | | | 8,446 | | | 3,178 | | | 2,732 | | | 5,910 | |
Total | | 6,951 | | | 6,328 | | | 13,279 | | | 4,743 | | | 6,430 | | | 11,173 | |
Medical Devices — | | | | | | | | | | | | |
Rhythm Management | | 775 | | | 830 | | | 1,605 | | | 776 | | | 881 | | | 1,657 | |
Electrophysiology | | 667 | | | 773 | | | 1,440 | | | 580 | | | 823 | | | 1,403 | |
Heart Failure | | 523 | | | 167 | | | 690 | | | 483 | | | 167 | | | 650 | |
Vascular | | 650 | | | 1,228 | | | 1,878 | | | 684 | | | 1,292 | | | 1,976 | |
Structural Heart | | 604 | | | 667 | | | 1,271 | | | 537 | | | 654 | | | 1,191 | |
Neuromodulation | | 456 | | | 112 | | | 568 | | | 460 | | | 124 | | | 584 | |
Diabetes Care | | 1,165 | | | 2,320 | | | 3,485 | | | 865 | | | 2,292 | | | 3,157 | |
Total | | 4,840 | | | 6,097 | | | 10,937 | | | 4,385 | | | 6,233 | | | 10,618 | |
| | | | | | | | | | | | |
Other | | 8 | | | — | | | 8 | | | 31 | | | 18 | | | 49 | |
| | | | | | | | | | | | |
Total | | $ | 13,923 | | | $ | 19,639 | | | $ | 33,562 | | | $ | 11,787 | | | $ | 19,820 | | | $ | 31,607 | |
Remaining Performance Obligations
As of September 30, 2022,March 31, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $3.9$4.1 billion in the Diagnostics segment and approximately $433$450 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 1617 percent over the subsequent 12 months and the remainder thereafter.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 3 — Revenue (Continued)
These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Financial Accounting Standards Board (FASB)FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 2 — Revenue (Continued)
Other Contract Assets and Liabilities
Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.
Changes in the contract liabilities during the period are as follows:
| | | | | | | | |
(in millions) | | |
Contract Liabilities: | | |
Balance at December 31, 20212022 | | $ | 520500 | |
Unearned revenue from cash received during the period | | 466122 | |
Revenue recognized related to contract liability balance | | (508)(93) | |
Balance at September 30, 2022March 31, 2023 | | $ | 478529 | |
Note 34 — Supplemental Financial Information
Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September 30,March 31, 2023 and 2022 and 2021 were $1.429$1.313 billion and $2.092 billion, respectively, and for the nine months ended September 30, 2022 and 2021 were $5.876 billion and $5.061$2.438 billion, respectively.
Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first ninethree months of 20222023 includes $362$282 million of pension contributions and the payment of cash taxes of approximately $987$122 million. The first ninethree months of 20212022 includes $366$334 million of pension contributions and the payment of cash taxes of approximately $990$195 million.
The following summarizes the activity for the first ninethree months of 20222023 related to the allowance for doubtful accounts as of September 30, 2022:March 31, 2023:
| | | | | | | | |
(in millions) | | |
Allowance for Doubtful Accounts: | | |
Balance at December 31, 20212022 | | $ | 313262 | |
Provisions/charges to income | | 108 | |
Amounts charged off and other deductionsadjustments | | (49)2 | |
Balance at September 30, 2022March 31, 2023 | | $ | 274272 | |
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 4 — Supplemental Financial Information (Continued)
The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 3 — Supplemental Financial Information (Continued)
The components of long-term investments as of September 30, 2022March 31, 2023 and December 31, 20212022 are as follows:
| (in millions) | (in millions) | | September 30, 2022 | | December 31, 2021 | (in millions) | | March 31, 2023 | | December 31, 2022 |
Long-term Investments: | Long-term Investments: | | | | | Long-term Investments: | | | | |
Equity securities | Equity securities | | $ | 604 | | | $ | 748 | | Equity securities | | $ | 565 | | | $ | 558 | |
Other | Other | | 160 | | | 68 | | Other | | 211 | | | 208 | |
Total | Total | | $ | 764 | | | $ | 816 | | Total | | $ | 776 | | | $ | 766 | |
The decreaseincrease in Abbott’s long-term investments as of September 30, 2022March 31, 2023 versus the balance as of December 31, 20212022 primarily relates to a decreasean increase in the value of investmentssecurities held in a rabbi trust and the impact ofadditional investments,partially offset by equity method investment losses partially offset by an investment in long-term time deposits.losses.
Abbott’s equity securities as of September 30, 2022,March 31, 2023, include $285$305 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of September 30, 2022March 31, 2023 with a carrying value of $228$162 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $83$88 million that do not have a readily determinable fair value.
In September 2021, Abbott acquired 100 percent of Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott’s condensed consolidated financial statements.
Note 45 — Changes In Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:
| | | Three Months Ended September 30 | | Three Months Ended March 31 |
| | Cumulative Foreign Currency Translation (Loss) Adjustments | | Net Actuarial (Losses) and Prior Service (Costs) and Credits | | Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other | | Cumulative Foreign Currency Translation (Loss) Adjustments | | Net Actuarial (Losses) and Prior Service (Costs) and Credits | | Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other |
(in millions) | (in millions) | | 2022 | | 2021 | | 2022 | | 2021 | | 2022 | | 2021 | (in millions) | | 2023 | | 2022 | | 2023 | | 2022 | | 2023 | | 2022 |
Balance at June 30 | | $ | (6,260) | | | $ | (5,230) | | | $ | (2,554) | | | $ | (3,738) | | | $ | 108 | | | $ | (98) | | |
Balance at January 1 | | Balance at January 1 | | $ | (6,733) | | | $ | (5,839) | | | $ | (1,493) | | | $ | (2,670) | | | $ | 175 | | | $ | 135 | |
Other comprehensive income (loss) before reclassifications | Other comprehensive income (loss) before reclassifications | | (1,008) | | | (391) | | | 15 | | | 16 | | | 278 | | | 70 | | Other comprehensive income (loss) before reclassifications | | 139 | | | (106) | | | 2 | | | 17 | | | (42) | | | (34) | |
Amounts reclassified from accumulated other comprehensive income | Amounts reclassified from accumulated other comprehensive income | | — | | | — | | | 41 | | | 62 | | | (65) | | | 69 | | Amounts reclassified from accumulated other comprehensive income | | — | | | — | | | — | | | 45 | | | (87) | | | (22) | |
Net current period comprehensive income (loss) | Net current period comprehensive income (loss) | | (1,008) | | | (391) | | | 56 | | | 78 | | | 213 | | | 139 | | Net current period comprehensive income (loss) | | 139 | | | (106) | | | 2 | | | 62 | | | (129) | | | (56) | |
Balance at September 30 | | $ | (7,268) | | | $ | (5,621) | | | $ | (2,498) | | | $ | (3,660) | | | $ | 321 | | | $ | 41 | | |
Balance at March 31 | | Balance at March 31 | | $ | (6,594) | | | $ | (5,945) | | | $ | (1,491) | | | $ | (2,608) | | | $ | 46 | | | $ | 79 | |
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022March 31, 2023
(Unaudited)
Note 45 — Changes In Accumulated Other Comprehensive Income (Loss) (Continued)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Nine Months Ended September 30 |
| | Cumulative Foreign Currency Translation (Loss) Adjustments | | Net Actuarial (Losses) and Prior Service (Costs) and Credits | | Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other |
(in millions) | | 2022 | | 2021 | | 2022 | | 2021 | | 2022 | | 2021 |
Balance at January 1 | | $ | (5,839) | | | $ | (4,859) | | | $ | (2,670) | | | $ | (3,871) | | | $ | 135 | | | $ | (216) | |
Other comprehensive income (loss) before reclassifications | | (1,429) | | | (762) | | | 45 | | | 26 | | | 289 | | | 138 | |
Amounts reclassified from accumulated other comprehensive income | | — | | | — | | | 127 | | | 185 | | | (103) | | | 119 | |
Net current period comprehensive income (loss) | | (1,429) | | | (762) | | | 172 | | | 211 | | | 186 | | | 257 | |
Balance at September 30 | | $ | (7,268) | | | $ | (5,621) | | | $ | (2,498) | | | $ | (3,660) | | | $ | 321 | | | $ | 41 | |
Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 1112 for additional details.
Note 56 — Goodwill and Intangible Assets
The total amount of goodwill reported was $22.3$22.9 billion at September 30, 2022March 31, 2023 and $23.2$22.8 billion at December 31, 2021.2022. Foreign currency translation adjustments decreasedincreased goodwill by approximately $946$128 million in the first ninethree months of 2022.2023. The amount of goodwill related to reportable segments at September 30, 2022March 31, 2023 was $2.6$2.7 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $15.9$16.4 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first ninethree months of 2022.2023.
The gross amount of amortizable intangible assets, primarily product rights and technology, was $26.9$27.4 billion and $27.7$27.2 billion as of September 30, 2022March 31, 2023 and December 31, 2021,2022, respectively. Accumulated amortization was $16.9$18.2 billion and $15.9$17.6 billion as of September 30, 2022March 31, 2023 and December 31, 2021,2022, respectively. Foreign currency translation adjustments decreasedincreased intangible assets by $250$43 million in the first ninethree months of 2022.2023. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2022, $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025, and $1.6$1.5 billion in 2026.2026 and $1.2 billion in 2027.
Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately $807 million as of September 30, 2022March 31, 2023 and $919 million as of December 31, 2021. In the third quarter of 2022, $111 million of impairment charges were recorded on the Research and development line of the Condensed Consolidated Statement of Earnings related to certain IPR&D intangible assets associated with the Medical Devices business segment.2022.
Note 67 — Restructuring Plans
On May 27, 2021,In 2022 and 2023, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter of 2021 included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 6 — Restructuring Plans (Continued)
In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in the second half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter of 2021 or Abbott settled with the counterparty in the second half of 2021.
The following summarizes the activity related to this restructuring action and the status of the related accruals as of September 30, 2022:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | | Inventory- Related Charges | | Fixed Asset Write-Downs | | Other Exit Costs | | Total |
Restructuring charges recorded in 2021 | | $ | 248 | | | $ | 80 | | | $ | 113 | | | $ | 441 | |
Payments | | — | | | — | | | (90) | | | (90) | |
Other non-cash | | (248) | | | (80) | | | — | | | (328) | |
Accrued balance at December 31, 2021 | | — | | | — | | | 23 | | | 23 | |
Payments and other adjustments | | — | | | — | | | (10) | | | (10) | |
Accrued balance at September 30, 2022 | | $ | — | | | $ | — | | | $ | 13 | | | $ | 13 | |
In 2021, Abbott management approvedvarious plans to streamline operations in order to reduce costs and improve efficiencies in Abbott’s diagnostic, established pharmaceutical, and nutritional businesses. In 2022 and 2021, Abbott management approved plans to streamline operations in its medical devices, segment.nutritional, diagnostic, and established pharmaceutical businesses. In the first three months of 2023, Abbott recorded employees-relatedemployee related severance and other charges of approximately $12$17 million, in the first nine months of 2022 of which approximately $5$6 million was recorded in Cost of products sold, approximately $2 million was recorded in Research and development, and approximately $5$11 million was recorded in Selling, general and administrative expense.expenses.
The following summarizes the activity forrelated to these restructurings:restructuring actions and the status of the related accruals as of March 31, 2023:
| | | | | | | | |
(in millions) | | |
Restructuring charges recorded in 2021Accrued balance at December 31, 2022 | | $ | 68228 | |
Restructuring charges in 2023 | | 17 | |
Payments and other adjustments | | (7)(61) | |
Accrued balance at DecemberMarch 31, 2021 | | 61 | |
Restructuring charges recorded in 2022 | | 12 | |
Payments and other adjustments | | (39) | |
Accrued balance at September 30, 20222023 | | $ | 34184 | |
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022March 31, 2023
(Unaudited)
Note 78 — Incentive Stock ProgramPrograms
In the first ninethree months of 2022,2023, Abbott granted 2,634,6471,887,093 stock options, 514,205445,278 restricted stock awards and 5,427,6974,761,433 restricted stock units under its incentive stock program. At September 30, 2022,March 31, 2023, approximately 8774 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September 30, 2022March 31, 2023 is as follows:
| | | Outstanding | | Exercisable | | Outstanding | | Exercisable |
Number of shares | Number of shares | | 29,048,449 | | | 23,310,464 | | Number of shares | | 29,760,644 | | | 25,107,006 | |
Weighted average remaining life (years) | Weighted average remaining life (years) | | 5.4 | | 4.6 | Weighted average remaining life (years) | | 5.4 | | 4.7 |
Weighted average exercise price | Weighted average exercise price | | $ | 70.22 | | | $ | 59.69 | | Weighted average exercise price | | $ | 73.33 | | | $ | 65.76 | |
Aggregate intrinsic value (in millions) | Aggregate intrinsic value (in millions) | | $ | 901 | | | $ | 890 | | Aggregate intrinsic value (in millions) | | $ | 947 | | | $ | 946 | |
The total unrecognized share-based compensation cost at September 30, 2022March 31, 2023 amounted to approximately $600$760 million, which is expected to be recognized over the next three years.
Note 89 — Debt and Lines of Credit
On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.
Note 910 — Financial Instruments, Derivatives and Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.9$7.1 billion at September 30, 2022March 31, 2023 and $8.6$7.7 billion at December 31, 2021,2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2022March 31, 2023 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, 2022March 31, 2023 and December 31, 2021,2022, Abbott held the gross notional amounts of $10.3$11.4 billion and $12.2$12.0 billion, respectively, of such foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of approximately $413$451 million and $521$446 million as of September 30, 2022March 31, 2023 and December 31, 2021,2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts with a notional valuesamount totaling approximately $2.9 billion at September 30, 2022March 31, 2023 and December 31, 20212022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022March 31, 2023
(Unaudited)
Note 910 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2022March 31, 2023 and December 31, 2021:2022:
| | | Fair Value - Assets | | Fair Value - Liabilities | | Fair Value - Assets | | Fair Value - Liabilities |
(in millions) | (in millions) | | September 30, 2022 | | Dec. 31, 2021 | | Balance Sheet Caption | | September 30, 2022 | | Dec. 31, 2021 | | Balance Sheet Caption | (in millions) | | March 31, 2023 | | December 31, 2022 | | Balance Sheet Caption | | March 31, 2023 | | December 31, 2022 | | Balance Sheet Caption |
Interest rate swaps designated as fair value hedges | | $ | — | | | $ | 87 | | | Deferred income taxes and other assets | | $ | 166 | | | $ | — | | | Post-employment obligations, deferred income taxes and other long-term liabilities | |
Interest rate swaps designated as fair value hedges: | | Interest rate swaps designated as fair value hedges: | | | | | | | | | | | | |
Non-current | | Non-current | | $ | — | | | $ | — | | | Deferred income taxes and other assets | | $ | 126 | | | $ | 136 | | | Post-employment obligations, deferred income taxes and other long-term liabilities |
Current | | Current | | — | | | — | | | Prepaid expenses and other receivables | | 21 | | | 20 | | | Other accrued liabilities |
Foreign currency forward exchange contracts: | Foreign currency forward exchange contracts: | | Foreign currency forward exchange contracts: | |
Hedging instruments | Hedging instruments | | 760 | | | 222 | | | Prepaid expenses and other receivables | | 66 | | | 65 | | | Other accrued liabilities | Hedging instruments | | 76 | | | 304 | | | Prepaid expenses and other receivables | | 139 | | | 96 | | | Other accrued liabilities |
Others not designated as hedges | Others not designated as hedges | | 148 | | | 70 | | | Prepaid expenses and other receivables | | 141 | | | 32 | | | Other accrued liabilities | Others not designated as hedges | | 78 | | | 108 | | | Prepaid expenses and other receivables | | 96 | | | 130 | | | Other accrued liabilities |
Debt designated as a hedge of net investment in a foreign subsidiary | Debt designated as a hedge of net investment in a foreign subsidiary | | — | | | — | | | n/a | | 413 | | | 521 | | | Long-term debt | Debt designated as a hedge of net investment in a foreign subsidiary | | — | | | — | | | n/a | | 451 | | | 446 | | | Long-term debt |
| | $ | 908 | | | $ | 379 | | | $ | 786 | | | $ | 618 | | | | $ | 154 | | | $ | 412 | | | $ | 833 | | | $ | 828 | | |
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2022March 31, 2023 and 2021.2022.
| | | Gain (loss) Recognized in Other Comprehensive Income (loss) | | Income (expense) and Gain (loss) Reclassified into Income | | | Gain (loss) Recognized in Other Comprehensive Income (loss) | | Income (expense) and Gain (loss) Reclassified into Income | |
| | Three Months Ended September 30 | | Nine Months Ended September 30 | | Three Months Ended September 30 | | Nine Months Ended September 30 | | | Three Months Ended March 31 | | | Three Months Ended March 31 | | |
(in millions) | (in millions) | | 2022 | | 2021 | | 2022 | | 2021 | | 2022 | | 2021 | | 2022 | | 2021 | | Income Statement Caption | (in millions) | | 2023 | | 2022 | | 2023 | | 2022 | | Income Statement Caption |
Foreign currency forward exchange contracts designated as cash flow hedges | Foreign currency forward exchange contracts designated as cash flow hedges | | $ | 350 | | | $ | 96 | | | $ | 442 | | | $ | 142 | | | $ | 79 | | | $ | (92) | | | $ | 149 | | | $ | (207) | | | Cost of products sold | Foreign currency forward exchange contracts designated as cash flow hedges | | $ | (63) | | | $ | (49) | | | $ | 126 | | | $ | 27 | | | Cost of products sold |
Debt designated as a hedge of net investment in a foreign subsidiary | Debt designated as a hedge of net investment in a foreign subsidiary | | 24 | | | 4 | | | 108 | | | 41 | | | — | | | — | | | — | | | — | | | n/a | Debt designated as a hedge of net investment in a foreign subsidiary | | (5) | | | 30 | | | — | | | — | | | n/a |
Interest rate swaps designated as fair value hedges | Interest rate swaps designated as fair value hedges | | n/a | | n/a | | n/a | | n/a | | (85) | | | (14) | | | (253) | | | (81) | | | Interest expense | Interest rate swaps designated as fair value hedges | | n/a | | n/a | | 9 | | | (121) | | | Interest expense |
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022March 31, 2023
(Unaudited)
Note 910 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
Losses of $27$103 million and $18$51 million were recognized in the three months ended September 30,March 31, 2023 and 2022, and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $225 million and $15 million were recognized in the nine months ended September 30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.
The carrying values and fair values of certain financial instruments as of September 30, 2022March 31, 2023 and December 31, 20212022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.
| | | September 30, 2022 | | December 31, 2021 | | March 31, 2023 | | December 31, 2022 |
(in millions) | (in millions) | | Carrying Value | | Fair Value | | Carrying Value | | Fair Value | (in millions) | | Carrying Value | | Fair Value | | Carrying Value | | Fair Value |
Long-term Investment Securities: | Long-term Investment Securities: | | | | | | | | | Long-term Investment Securities: | | | | | | | | |
Equity securities | Equity securities | | $ | 604 | | | $ | 604 | | | $ | 748 | | | $ | 748 | | Equity securities | | $ | 565 | | | $ | 565 | | | $ | 558 | | | $ | 558 | |
Other | Other | | 160 | | | 160 | | | 68 | | | 68 | | Other | | 211 | | | 211 | | | 208 | | | 208 | |
Total Long-term Debt | Total Long-term Debt | | (16,414) | | | (15,821) | | | (18,050) | | | (21,152) | | Total Long-term Debt | | (16,900) | | | (16,927) | | | (16,773) | | | (16,313) | |
Foreign Currency Forward Exchange Contracts: | Foreign Currency Forward Exchange Contracts: | | | | | | | | Foreign Currency Forward Exchange Contracts: | | | | | | | |
Receivable position | Receivable position | | 908 | | | 908 | | | 292 | | | 292 | | Receivable position | | 154 | | | 154 | | | 412 | | | 412 | |
(Payable) position | (Payable) position | | (207) | | | (207) | | | (97) | | | (97) | | (Payable) position | | (235) | | | (235) | | | (226) | | | (226) | |
Interest Rate Hedge Contracts: | Interest Rate Hedge Contracts: | | | | | | | | | Interest Rate Hedge Contracts: | | | | | | | | |
Receivable position | | — | | | — | | | 87 | | | 87 | | |
| (Payable) position | (Payable) position | | (166) | | | (166) | | | — | | | — | | (Payable) position | | (147) | | | (147) | | | (156) | | | (156) | |
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022March 31, 2023
(Unaudited)
Note 910 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
| | | Basis of Fair Value Measurement | | Basis of Fair Value Measurement |
(in millions) | (in millions) | | Outstanding Balances | | Quoted Prices in Active Markets | | Significant Other Observable Inputs | | Significant Unobservable Inputs | (in millions) | | Outstanding Balances | | Quoted Prices in Active Markets | | Significant Other Observable Inputs | | Significant Unobservable Inputs |
September 30, 2022: | | | | | | | | | |
March 31, 2023: | | March 31, 2023: | | | | | | | | |
Equity securities | Equity securities | | $ | 293 | | | $ | 293 | | | $ | — | | | $ | — | | Equity securities | | $ | 315 | | | $ | 315 | | | $ | — | | | $ | — | |
Foreign currency forward exchange contracts | Foreign currency forward exchange contracts | | 908 | | | — | | | 908 | | | — | | Foreign currency forward exchange contracts | | 154 | | | — | | | 154 | | | — | |
Total Assets | Total Assets | | $ | 1,201 | | | $ | 293 | | | $ | 908 | | | $ | — | | Total Assets | | $ | 469 | | | $ | 315 | | | $ | 154 | | | $ | — | |
| Fair value of hedged long-term debt | Fair value of hedged long-term debt | | $ | 2,685 | | | $ | — | | | $ | 2,685 | | | $ | — | | Fair value of hedged long-term debt | | $ | 2,720 | | | $ | — | | | $ | 2,720 | | | $ | — | |
Interest rate swap derivative financial instruments | Interest rate swap derivative financial instruments | | 166 | | | — | | | 166 | | | — | | Interest rate swap derivative financial instruments | | 147 | | | — | | | 147 | | | — | |
Foreign currency forward exchange contracts | Foreign currency forward exchange contracts | | 207 | | | — | | | 207 | | | — | | Foreign currency forward exchange contracts | | 235 | | | — | | | 235 | | | — | |
Contingent consideration related to business combinations | Contingent consideration related to business combinations | | 138 | | | — | | | — | | | 138 | | Contingent consideration related to business combinations | | 133 | | | — | | | — | | | 133 | |
Total Liabilities | Total Liabilities | | $ | 3,196 | | | $ | — | | | $ | 3,058 | | | $ | 138 | | Total Liabilities | | $ | 3,235 | | | $ | — | | | $ | 3,102 | | | $ | 133 | |
| December 31, 2021: | | |
December 31, 2022: | | December 31, 2022: | |
Equity securities | Equity securities | | $ | 402 | | | $ | 402 | | | $ | — | | | $ | — | | Equity securities | | $ | 307 | | | $ | 307 | | | $ | — | | | $ | — | |
Interest rate swap derivative financial instruments | | 87 | | | — | | | 87 | | | — | | |
| Foreign currency forward exchange contracts | Foreign currency forward exchange contracts | | 292 | | | — | | | 292 | | | — | | Foreign currency forward exchange contracts | | 412 | | | — | | | 412 | | | — | |
Total Assets | Total Assets | | $ | 781 | | | $ | 402 | | | $ | 379 | | | $ | — | | Total Assets | | $ | 719 | | | $ | 307 | | | $ | 412 | | | $ | — | |
| Fair value of hedged long-term debt | Fair value of hedged long-term debt | | $ | 2,926 | | | $ | — | | | $ | 2,926 | | | $ | — | | Fair value of hedged long-term debt | | $ | 2,691 | | | $ | — | | | $ | 2,691 | | | $ | — | |
Interest rate swap derivative financial instruments | | Interest rate swap derivative financial instruments | | 156 | | | — | | | 156 | | | — | |
Foreign currency forward exchange contracts | Foreign currency forward exchange contracts | | 97 | | | — | | | 97 | | | — | | Foreign currency forward exchange contracts | | 226 | | | — | | | 226 | | | — | |
Contingent consideration related to business combinations | Contingent consideration related to business combinations | | 130 | | | — | | | — | | | 130 | | Contingent consideration related to business combinations | | 130 | | | — | | | — | | | 130 | |
Total Liabilities | Total Liabilities | | $ | 3,153 | | | $ | — | | | $ | 3,023 | | | $ | 130 | | Total Liabilities | | $ | 3,203 | | | $ | — | | | $ | 3,073 | | | $ | 130 | |
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.
Note 1011 — Litigation and Environmental Matters
Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022March 31, 2023
(Unaudited)
Note 1011 — Litigation and Environmental Matters (Continued)
Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40$25 million to $50$35 million. The recorded accrual balance at September 30, 2022March 31, 2023 for these proceedings and exposures was approximately $45$30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.
Note 1112 — Post-Employment Benefits
Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September 30March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:
| | | Defined Benefit Plans | | Medical and Dental Plans | | Defined Benefit Plans | | Medical and Dental Plans |
| | Three Months Ended Sept. 30 | | Nine Months Ended Sept. 30 | | Three Months Ended Sept. 30 | | Nine Months Ended Sept. 30 | | Three Months Ended March 31 | | | Three Months Ended March 31 |
(in millions) | (in millions) | | 2022 | | 2021 | | 2022 | | 2021 | | 2022 | | 2021 | | 2022 | | 2021 | (in millions) | | 2023 | | 2022 | | 2023 | | 2022 |
Service cost - benefits earned during the period | Service cost - benefits earned during the period | | $ | 92 | | | $ | 98 | | | $ | 282 | | | $ | 294 | | | $ | 13 | | | $ | 14 | | | $ | 38 | | | $ | 42 | | Service cost - benefits earned during the period | | $ | 60 | | | $ | 96 | | | $ | 9 | | | $ | 13 | |
Interest cost on projected benefit obligations | Interest cost on projected benefit obligations | | 74 | | | 62 | | | 225 | | | 186 | | | 9 | | | 8 | | | 27 | | | 25 | | Interest cost on projected benefit obligations | | 114 | | | 76 | | | 14 | | | 10 | |
Expected return on plan assets | Expected return on plan assets | | (231) | | | (211) | | | (701) | | | (633) | | | (8) | | | (6) | | | (23) | | | (20) | | Expected return on plan assets | | (242) | | | (236) | | | (6) | | | (7) | |
Net amortization of: | Net amortization of: | | Net amortization of: | |
Actuarial loss, net | Actuarial loss, net | | 58 | | | 79 | | | 174 | | | 238 | | | 2 | | | 7 | | | 8 | | | 21 | | Actuarial loss, net | | 3 | | | 59 | | | — | | | 5 | |
Prior service cost (credit) | Prior service cost (credit) | | — | | | — | | | 1 | | | 1 | | | (6) | | | (7) | | | (18) | | | (21) | | Prior service cost (credit) | | — | | | — | | | (3) | | | (6) | |
Net cost (credit) | Net cost (credit) | | $ | (7) | | | $ | 28 | | | $ | (19) | | | $ | 86 | | | $ | 10 | | | $ | 16 | | | $ | 32 | | | $ | 47 | | Net cost (credit) | | $ | (65) | | | $ | (5) | | | $ | 14 | | | $ | 15 | |
Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first ninethree months of 2023 and 2022, and 2021, $362$282 million and $366$334 million, respectively, were contributed to defined benefit plans. In the first ninethree months of 20222023 and 2021,2022, $28 millionand$26 million, respectively, were was contributed in each year to the post-employment medical and dental plans.
Note 1213 — Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first ninethree months of 20222023 and 2021,2022, taxes on earnings include approximately $36$3 million and $97$30 million, respectively, in excess tax benefits associated with share-based compensation. In the first ninethree months of 2023 and 2022, taxes on earnings also include approximately $20$22 million and $30 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.
Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $100$80 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022March 31, 2023
(Unaudited)
Note 1314 — Segment Information
Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories physician offices and alternate-care testing sites. For segment reporting purposes, the Core LaboratoryLaboratories Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.
Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022March 31, 2023
(Unaudited)
Note 1314 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
| | | | Net Sales to External Customers | | Operating Earnings | | | Net Sales to External Customers | | Operating Earnings |
| | Three Months Ended Sept. 30 | | Nine Months Ended Sept. 30 | | Three Months Ended Sept. 30 | | Nine Months Ended Sept. 30 | | Three Months Ended March 31 | | Three Months Ended March 31 |
(in millions) | (in millions) | | 2022 | | 2021 | | 2022 | | 2021 | | 2022 | | 2021 | | 2022 | | 2021 | (in millions) | | 2023 | | 2022 | | 2023 | | 2022 |
Established Pharmaceutical Products | Established Pharmaceutical Products | | $ | 1,326 | | | $ | 1,265 | | | $ | 3,696 | | | $ | 3,515 | | | $ | 331 | | | $ | 293 | | | $ | 831 | | | $ | 682 | | Established Pharmaceutical Products | | $ | 1,189 | | | $ | 1,147 | | | $ | 300 | | | $ | 242 | |
Nutritional Products | Nutritional Products | | 1,795 | | | 2,108 | | | 5,642 | | | 6,252 | | | 69 | | | 431 | | | 550 | | | 1,388 | | Nutritional Products | | 1,967 | | | 1,894 | | | 380 | | | 251 | |
Diagnostic Products | Diagnostic Products | | 3,671 | | | 3,912 | | | 13,279 | | | 11,173 | | | 1,352 | | | 1,652 | | | 5,631 | | | 4,429 | | Diagnostic Products | | 2,688 | | | 5,257 | | | 651 | | | 2,564 | |
Medical Devices | Medical Devices | | 3,615 | | | 3,632 | | | 10,937 | | | 10,618 | | | 1,039 | | | 1,160 | | | 3,272 | | | 3,375 | | Medical Devices | | 3,900 | | | 3,594 | | | 1,078 | | | 1,083 | |
Total Reportable Segments | Total Reportable Segments | | 10,407 | | | 10,917 | | | 33,554 | | | 31,558 | | | 2,791 | | | 3,536 | | | 10,284 | | | 9,874 | | Total Reportable Segments | | 9,744 | | | 11,892 | | | 2,409 | | | 4,140 | |
Other | Other | | 3 | | | 11 | | | 8 | | | 49 | | | Other | | 3 | | | 3 | | |
Net sales | Net sales | | $ | 10,410 | | | $ | 10,928 | | | $ | 33,562 | | | $ | 31,607 | | | Net sales | | $ | 9,747 | | | $ | 11,895 | | |
Corporate functions and benefit plan costs | Corporate functions and benefit plan costs | | | | | | | | | | (115) | | | (204) | | | (352) | | | (450) | | Corporate functions and benefit plan costs | | | | | | (77) | | | (114) | |
Net interest expense | Net interest expense | | (86) | | | (123) | | | (309) | | | (370) | | Net interest expense | | (52) | | | (117) | |
Share-based compensation (a) | Share-based compensation (a) | | (123) | | | (114) | | | (570) | | | (534) | | Share-based compensation (a) | | (281) | | | (305) | |
Amortization of intangible assets | Amortization of intangible assets | | (498) | | | (520) | | | (1,517) | | | (1,533) | | Amortization of intangible assets | | (491) | | | (512) | |
Other, net (b) | Other, net (b) | | (211) | | | (82) | | | (550) | | | (1,103) | | Other, net (b) | | 54 | | | (216) | |
Earnings before taxes | Earnings before taxes | | $ | 1,758 | | | $ | 2,493 | | | $ | 6,986 | | | $ | 5,884 | | Earnings before taxes | | $ | 1,562 | | | $ | 2,876 | |
| | | | | |
Notes: | 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023. |
(a) | Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. |
| | | | | |
(b) | Other, net for the three and nine months ended September 30,March 31, 2022 includes $10$120 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&D intangible assets. Other, net for the three and nine months ended September 30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September 30, 2021 also includes costs related to certain litigation.segment. |
Note 15 — Subsequent Event
On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of approximately $850 million. The acquisition was funded with cash on hand. CSI sells an atherectomy system used in treating peripheral and coronary artery disease. The acquisition adds complementary technologies to Abbott’s portfolio of vascular device offerings. The transaction will be accounted for as a business combination. Abbott has begun the process of measuring, as of the acquisition date, the acquired assets and assumed liabilities. Preliminary purchase price allocation estimates will be disclosed in Abbott’s Form 10-Q for the period ending June 30, 2023.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Financial Review — Results of Operations
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.
The following tables detail sales by reportable segment for the three and nine months ended September 30.March 31. Percent changes are versus the prior year and are based on unrounded numbers.
| | | Net Sales to External Customers | | Net Sales to External Customers |
(in millions) | (in millions) | | Three Months Ended September 30, 2022 | | Three Months Ended September 30, 2021 | | Total Change | | Impact of Foreign Exchange | | Total Change Excl. Foreign Exchange | (in millions) | | Three Months Ended March 31, 2023 | | Three Months Ended March 31, 2022 | | Total Change | | Impact of Foreign Exchange | | Total Change Excl. Foreign Exchange |
| Established Pharmaceutical Products | Established Pharmaceutical Products | | $ | 1,326 | | | $ | 1,265 | | | 4.9 | % | | (7.3) | % | | 12.2 | % | Established Pharmaceutical Products | | $ | 1,189 | | | $ | 1,147 | | | 3.7 | % | | (7.4) | % | | 11.1 | % |
Nutritional Products | Nutritional Products | | 1,795 | | | 2,108 | | | (14.9) | | | (4.6) | | | (10.3) | | Nutritional Products | | 1,967 | | | 1,894 | | | 3.8 | | | (3.9) | | | 7.7 | |
Diagnostic Products | Diagnostic Products | | 3,671 | | | 3,912 | | | (6.2) | | | (5.6) | | | (0.6) | | Diagnostic Products | | 2,688 | | | 5,257 | | | (48.9) | | | (1.8) | | | (47.1) | |
Medical Devices | Medical Devices | | 3,615 | | | 3,632 | | | (0.5) | | | (6.9) | | | 6.4 | | Medical Devices | | 3,900 | | | 3,594 | | | 8.5 | | | (3.9) | | | 12.4 | |
Total Reportable Segments | Total Reportable Segments | | 10,407 | | | 10,917 | | | (4.7) | | | (6.0) | | | 1.3 | | Total Reportable Segments | | 9,744 | | | 11,892 | | | (18.1) | | | (3.3) | | | (14.8) | |
Other | Other | | 3 | | | 11 | | | n/m | | n/m | | n/m | Other | | 3 | | | 3 | | | n/m | | n/m | | n/m |
Net Sales | Net Sales | | $ | 10,410 | | | $ | 10,928 | | | (4.7) | | | (6.0) | | | 1.3 | | Net Sales | | $ | 9,747 | | | $ | 11,895 | | | (18.1) | | | (3.3) | | | (14.8) | |
| Total U.S. | Total U.S. | | $ | 4,094 | | | $ | 4,368 | | | (6.3) | | | — | | | (6.3) | | Total U.S. | | $ | 3,928 | | | $ | 4,937 | | | (20.4) | | | — | | | (20.4) | |
| Total International | Total International | | $ | 6,316 | | | $ | 6,560 | | | (3.7) | | | (10.0) | | | 6.3 | | Total International | | $ | 5,819 | | | $ | 6,958 | | | (16.4) | | | (5.7) | | | (10.7) | |
| | | | | |
Notes: | The Acelis Connected Health business was internally transferred from Diagnostic Products to Medical Devices on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Diagnostic Products to Medical Devices.
|
| In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. |
| n/m = Percent change is not meaningful |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Net Sales to External Customers |
(in millions) | | Nine Months Ended September 30, 2022 | | Nine Months Ended September 30, 2021 | | Total Change | | Impact of Foreign Exchange | | Total Change Excl. Foreign Exchange |
| | | | | | | | | | |
Established Pharmaceutical Products | | $ | 3,696 | | | $ | 3,515 | | | 5.2 | % | | (6.4) | % | | 11.6 | % |
Nutritional Products | | 5,642 | | | 6,252 | | | (9.8) | | | (3.4) | | | (6.4) | |
Diagnostic Products | | 13,279 | | | 11,173 | | | 18.9 | | | (4.2) | | | 23.1 | |
Medical Devices | | 10,937 | | | 10,618 | | | 3.0 | | | (5.4) | | | 8.4 | |
Total Reportable Segments | | 33,554 | | | 31,558 | | | 6.3 | | | (4.7) | | | 11.0 | |
Other | | 8 | | | 49 | | | n/m | | n/m | | n/m |
Net Sales | | $ | 33,562 | | | $ | 31,607 | | | 6.2 | | | (4.7) | | | 10.9 | |
| | | | | | | | | | |
Total U.S. | | $ | 13,923 | | | $ | 11,787 | | | 18.1 | | | — | | | 18.1 | |
| | | | | | | | | | |
Total International | | $ | 19,639 | | | $ | 19,820 | | | (0.9) | | | (7.4) | | | 6.5 | |
Notes:
In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
n/m = Percent change is not meaningful
The 1.314.8 percent increasedecrease in total net sales during the third quarterfirst three months of 2022,2023, excluding the impact of foreign exchange, reflected growththe decrease in the Medical Devices and Established Pharmaceutical Products segmentsdemand for Abbott’s rapid diagnostic tests to detect COVID-19, partially offset by lower Nutritional Products sales as well as a year-over-year decline in COVID-19 testing-related revenues.higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled approximately $1.7$730 million during the first quarter of 2023 and approximately $3.3 billion during the thirdfirst quarter of 2022 and approximately $1.9 billion during the third quarter of 2021.2022. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales decreased 3.1increased 4.9 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 3.2 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the third quarter as the relatively stronger U.S. dollar decreased total international sales by 10.0 percent and total sales by 6.0 percent.
The 10.9 percent increase in total net sales during the first nine months of 2022, excluding the impact of foreign exchange, reflected demand for Abbott’s rapid diagnostic tests to detect COVID-19 as well as growth in the Medical Devices and Established Pharmaceutical Products segments partially offset by lower Nutritional Products sales. Abbott’s COVID-19 testing-related sales totaled approximately $7.3 billion during the first nine months of 2022 and approximately $5.4 billion during the first nine months of 2021. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 0.1 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 4.99.4 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first nine monthsquarter as the relatively stronger U.S. dollar decreased total international sales by 7.45.7 percent and total sales by 4.73.3 percent.
Due to the unpredictability of the duration and impact of the currentdemand for COVID-19 pandemic,tests, the future extent to which the COVID-19 pandemic will have a material effect on Abbott’s business, financial condition or results of operations is uncertain.
The table below provides detail by sales category for the ninethree months ended September 30.March 31. Percent changes are versus the prior year and are based on unrounded numbers.
| (in millions) | (in millions) | | Sept. 30, 2022 | | Sept. 30, 2021 | | Total Change | | Impact of Foreign Exchange | | Total Change Excl. Foreign Exchange | (in millions) | | March 31, 2023 | | March 31, 2022 | | Total Change | | Impact of Foreign Exchange | | Total Change Excl. Foreign Exchange |
Established Pharmaceutical Products — | Established Pharmaceutical Products — | | | | | | | | | | | Established Pharmaceutical Products — | | | | | | | | | | |
Key Emerging Markets | Key Emerging Markets | | $ | 2,826 | | | $ | 2,672 | | | 5.8 | % | | (6.4) | % | | 12.2 | % | Key Emerging Markets | | $ | 912 | | | $ | 906 | | | 0.7 | % | | (7.6) | % | | 8.3 | % |
Other Emerging Markets | Other Emerging Markets | | 870 | | | 843 | | | 3.2 | | | (6.3) | | | 9.5 | | Other Emerging Markets | | 277 | | | 241 | | | 15.0 | | | (6.8) | | | 21.8 | |
| Nutritionals — | Nutritionals — | | Nutritionals — | |
International Pediatric Nutritionals | International Pediatric Nutritionals | | 1,491 | | | 1,637 | | | (8.9) | | | (4.3) | | | (4.6) | | International Pediatric Nutritionals | | 465 | | | 509 | | | (8.6) | | | (4.7) | | | (3.9) | |
U.S. Pediatric Nutritionals | U.S. Pediatric Nutritionals | | 1,108 | | | 1,622 | | | (31.7) | | | — | | | (31.7) | | U.S. Pediatric Nutritionals | | 459 | | | 338 | | | 36.1 | | | — | | | 36.1 | |
International Adult Nutritionals | International Adult Nutritionals | | 2,027 | | | 1,987 | | | 2.0 | | | (7.0) | | | 9.0 | | International Adult Nutritionals | | 690 | | | 708 | | | (2.6) | | | (7.0) | | | 4.4 | |
U.S. Adult Nutritionals | U.S. Adult Nutritionals | | 1,016 | | | 1,006 | | | 1.0 | | | — | | | 1.0 | | U.S. Adult Nutritionals | | 353 | | | 339 | | | 3.9 | | | — | | | 3.9 | |
| Diagnostics — | Diagnostics — | | Diagnostics — | |
Core Laboratory | Core Laboratory | | 3,624 | | | 3,780 | | | (4.1) | | | (5.7) | | | 1.6 | | Core Laboratory | | 1,182 | | | 1,184 | | | (0.2) | | | (5.3) | | | 5.1 | |
Molecular | Molecular | | 815 | | | 1,082 | | | (24.7) | | | (2.8) | | | (21.9) | | Molecular | | 147 | | | 420 | | | (65.0) | | | (1.0) | | | (64.0) | |
Point of Care | Point of Care | | 394 | | | 401 | | | (1.6) | | | (1.2) | | | (0.4) | | Point of Care | | 134 | | | 128 | | | 4.7 | | | (1.0) | | | 5.7 | |
Rapid Diagnostics | Rapid Diagnostics | | 8,446 | | | 5,910 | | | 42.9 | | | (3.8) | | | 46.7 | | Rapid Diagnostics | | 1,225 | | | 3,525 | | | (65.3) | | | (0.8) | | | (64.5) | |
| Medical Devices — | Medical Devices — | | Medical Devices — | |
Rhythm Management | Rhythm Management | | 1,605 | | | 1,657 | | | (3.2) | | | (4.5) | | | 1.3 | | Rhythm Management | | 527 | | | 524 | | | 0.4 | | | (3.6) | | | 4.0 | |
Electrophysiology | Electrophysiology | | 1,440 | | | 1,403 | | | 2.6 | | | (5.6) | | | 8.2 | | Electrophysiology | | 505 | | | 485 | | | 3.9 | | | (4.9) | | | 8.8 | |
Heart Failure | Heart Failure | | 690 | | | 650 | | | 6.2 | | | (2.4) | | | 8.6 | | Heart Failure | | 281 | | | 250 | | | 12.4 | | | (1.2) | | | 13.6 | |
Vascular | Vascular | | 1,878 | | | 1,976 | | | (5.0) | | | (4.9) | | | (0.1) | | Vascular | | 617 | | | 619 | | | (0.2) | | | (4.1) | | | 3.9 | |
Structural Heart | Structural Heart | | 1,271 | | | 1,191 | | | 6.7 | | | (6.1) | | | 12.8 | | Structural Heart | | 461 | | | 411 | | | 12.2 | | | (4.2) | | | 16.4 | |
Neuromodulation | Neuromodulation | | 568 | | | 584 | | | (2.7) | | | (2.1) | | | (0.6) | | Neuromodulation | | 196 | | | 179 | | | 9.4 | | | (1.8) | | | 11.2 | |
Diabetes Care | Diabetes Care | | 3,485 | | | 3,157 | | | 10.4 | | | (7.0) | | | 17.4 | | Diabetes Care | | 1,313 | | | 1,126 | | | 16.6 | | | (4.4) | | | 21.0 | |
Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Rapid Diagnostics to Heart Failure.
Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets for Established Pharmaceutical Products increased 12.28.3 percent in the first ninethree months of 2022,2023, led by double-digit growth in several countries, including IndiaBrazil, China and China,southeast Asia, and across several therapeutic areas, including gastroenterology,cardio-metabolic, respiratory, and central nervous system/pain management, and respiratory products.management. Other Emerging Markets, excluding the effect of foreign exchange, increased by 9.521.8 percent in the first ninethree months of 2022.2023.
InternationalExcluding the impact of foreign exchange, total Nutritional Products sales in the first three months of 2023 increased 7.7 percent. In U.S. Pediatric NutritionalNutritionals, the 36.1 percent increase in sales excludingin the first three months of 2023 reflects the impact of the unfavorable effects of the voluntary recall of certain infant formula products in the first quarter of 2022, partially offset by a decrease in 2023 Pedialyte® sales. Excluding the effect of foreign exchange, decreased 4.6 percent in the first nine months of 2022 versus the comparable 2021 period. The decrease reflects the impact of challenging market dynamics in the infant category in Greater China partially offset by higher sales volumes in various countries in Southeast Asia and Latin America. International Adult Nutritional sales, excluding the effect of foreign exchange, increased 9.0 percent, reflecting double digit growth of the Ensure® and Glucerna® brands in several countries in Southeast Asia and China. In the first nine months of 2022, U.S. Adult Nutritional sales increased 1.0 percent.
In U.S. Pediatric Nutritionals, Abbott initiated a voluntary recall in February 2022 of certain infant powder formula products manufactured at its facility in Sturgis, Michigan and stopped production at the facility. On May 16, 2022, Abbott entered into a consent decree with the U.S. Food and Drug Administration (FDA) on the steps necessary to resume production and maintain the Sturgis facility and operations. On July 1, Abbott restarted partial production at the facility starting with its specialty formula EleCare® and metabolic formulas. Subsequently, Abbott restarted Similac® production. The consent decree does not affect any other Abbott plant or operation.
During the first three quarters of 2022, Abbott took various actions to mitigate the impact of the recall on the supply of formula in the U.S. These actions included the shipment of infant formula powder into the U.S. from Abbott's FDA-registered facility in Ireland; prioritization of infant formula production at its Columbus, Ohio facility; conversion of other liquid manufacturing lines into manufacturing Similac liquid ready-to-feed product; increased production of powder infant formula at its Casa Grande, Arizona manufacturing site; and importation of product from its facility in Spain as permitted by the FDA.
The 31.73.9 percent decrease in U.S.International Pediatric Nutritional sales in the first ninethree months of 20222023 primarily reflects the impact of exiting the recall and the Sturgis production stoppagepediatric nutrition business in China, partially offset by increased demand for Abbott’s Pedialytegrowth in several other markets® products. U.S. sales of infant powder formula brands associated with the recall were $277 million and $900 million in the first nine months of 2022 and 2021, respectively..
Excluding the effect of foreign exchange, the increases of 3.9 percent in U.S. Adult Nutritionals and 4.4 percent in International Adult Nutritionals in the first three months of 2023 were led by growth of Ensure® products.
The 23.147.1 percent increasedecrease in Diagnostic Products sales in the first ninethree months of 2022,2023, excluding the impact of foreign exchange, was driven by lower demand for Abbott’s portfolio of COVID-19 tests intests. In Rapid Diagnostics, sales decreased 64.5 percent in the first three months of 2023, excluding the effect of foreign exchange, due to lower demand for COVID-19 tests. In the first three months of 2023 and growth in routine diagnostic testing in Molecular Diagnostics. 2022, Rapid Diagnostics COVID-19 testing-related sales were $704 million and $3.0 billion, respectively. In the first three months of 2023, Rapid Diagnostics sales increased 5.1 percent, excluding COVID-19 testing-related sales, and increased 8.0 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.
In Core Laboratory Diagnostics, sales increased 1.65.1 percent in the first ninethree months of 2022,2023, excluding the effect of foreign exchange, due to the higher volume of routine diagnostic testing from the continued roll-out of the Alinity® platformperformed in hospitals and an expanded menu of tests. These increases wereother laboratories, partially offset by lower test sales of Abbott’s laboratory-based tests for the detection of COVID-19 IgG and IgM antibodies, which determine if someone was previously infected with the COVID-19 virus, as well as market disruptions in China due to COVID-19 quarantine restrictions in various cities primarily during the second quarter of 2022.antibodies. In the first ninethree months of 20222023 and 2021,2022, Core Laboratory Diagnostics IgG and IgM antibodyCOVID-19 testing-related sales on Abbott’s ARCHITECT and Alinity i platforms were $51$6 million and $159$28 million, respectively. In the first ninethree months of 2022,2023, Core Laboratory Diagnostics sales decreased 1.3increased 1.7 percent, excluding COVID-19 testing-related sales, and increased 4.67.1 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.
The 64.0 percent decrease in Molecular Diagnostics sales in the first three months of 2023, excluding the effect of foreign exchange, was driven by lower demand for laboratory-based molecular tests for COVID-19 as well as lower demand for respiratory testing compared to significantly higher-than-usual demand in the first quarter of 2022. In the first three months of 2023 and 2022, Molecular Diagnostics COVID-19 testing-related sales were $20 million and $246 million, respectively. In the first three months of 2023, Molecular Diagnostics sales decreased 27.1 percent, excluding COVID-19 testing-related sales, and decreased 24.8 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.
The 21.9 percent decrease in Molecular Diagnostics sales in the first nine months of 2022, excluding the effect of foreign exchange, was driven by lower demand for Abbott’s laboratory-based molecular tests for COVID-19 partially offset by growth in the base business from increased routine molecular testing. In the first nine months of 2022 and 2021, Molecular Diagnostics COVID-19 testing-related sales were $375 million and $699 million, respectively. In the first nine months of 2022, Molecular Diagnostics sales increased 14.9 percent, excluding COVID-19 testing-related sales, and increased 19.4 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.
In Rapid Diagnostics, sales increased 46.7 percent in the first nine months of 2022, excluding the effect of foreign exchange, due to the demand for Abbott’s COVID-19 tests on its rapid testing platforms, including the Panbio® system, the ID NOW® platform, and the BinaxNOW® COVID-19 Ag Card test. In the first nine months of 2022 and 2021, Rapid Diagnostics COVID-19 testing-related sales were $6.9 billion and $4.5 billion, respectively. In the first nine months of 2022, Rapid Diagnostics sales increased 11.8 percent, excluding COVID-19 testing-related sales, and increased 14.6 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.These increases reflect higher sales
of ID NOW tests for flu, strep, and respiratory syncytial virus (RSV) as well as growth in various other Rapid Diagnostics products.
Excluding the effect of foreign exchange, total Medical Devices sales grew 8.412.4 percent in the first ninethree months of 2022, driven2023, led by double-digit growth in Diabetes Care, Electrophysiology, Structural Heart, Heart Failure and Heart Failure. Growth inNeuromodulation. Higher Diabetes Care sales waswere driven by continued growth of FreeStyle Libre®, Abbott’s continuous glucose monitoring system, in the U.S. and internationally. FreeStyle Libre sales totaled $3.1$1.2 billion in the first ninethree months of 2022,2023, which reflected a 22.825.4 percent increase, excluding the effect of foreign exchange, over the first ninethree months of 20212022 when FreeStyle Libre sales totaled $2.7$1.0 billion. During the third quarter of 2022, Abbott launched its FreeStyle Libre 3 system in the U.S., which automatically delivers up-to-the-minute glucose readings and 14-day accuracy in a wearable sensor.
During the first ninethree months of 2022,2023, procedure volumes increased across Abbott’sthe cardiovascular and neuromodulation businesses were negatively impacted by new surges of COVID-19businesses. In Structural Heart, the 16.4 percent increase in various geographies as well as intermittent COVID-19 lockdown restrictions in China and healthcare staffing challenges throughout the nine months. Despite such challenges, overall volume trends improved in several businesses versus the first nine months of 2021. In Electrophysiology, the 8.2 percent growth,sales, excluding the effect of foreign exchange, reflects an acceleration in the growth of the MitraClip® product along with contributions from recently launched products, including Amulet®, Navitor®, and TriClip®. In Vascular, the 3.9 percent increase in procedure volumes andsales, excluding the continued roll‑outimpact of Abbott’s EnSite® X EP System with Ensite Omnipolar Technology (OT), a new cardiac mapping platform availableforeign exchange, during the first three months of 2023 primarily reflects double-digit growth in the U.S., Japan and across Europe. In January 2022, Abbott announced FDA clearance for the EnSiteendovascular sales.
GrowthIn Electrophysiology, the 8.8 percent increase in Structural Heart duringsales, excluding the first nine monthseffect of 2022,foreign exchange, primarily reflects higher procedure volumes in various European countries and the U.S. In Neuromodulation the 11.2 percent increase in sales, excluding the effect of foreign exchange, was 12.8 percent, driven by growth across several areasthe recent launch of the business, including AmplatzerEterna®_Amulet®TM Left Atrial Appendage Occluder, which offers immediate closure of the left atrial appendage, an area in the heart where blood clots can form and MitraClip®, Abbott's market-leading devicerechargeable spinal cord stimulation system for the minimally invasive treatment of mitral regurgitation, a leaky heart valve. In Vascular, sales during the first nine months of 2022, excluding the impact of foreign exchange, were virtually unchanged as higher endovascular sales were offset by the negative effect of lower average pricing for drug-eluting stents (DES) in the U.S. and a lag in the recovery of percutaneous coronary intervention case rateschronic pain along with market growth compared to many other cardiovascular procedures.the prior year period.
In the first ninethree months of 2022,2023, Medical Devices received various other product approvals. In February 2022,January 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) had approved Navitor, Abbott's second-generation transcatheter aortic valve implantation system to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. In March 2023, Abbott's Freestyle Libre continuous glucose monitoring system received U.S. FDA approvalclearance for an expanded indication for its CardioMEMSintegration with automated insulin delivery systems. In March 2023, the U.S. FDA approved Abbott's Epic® HF system, a small implantable sensor and remote monitoring system that can detect early warning signs of worsening heart failure. In April 2022, Abbott announced FDA approval for its Aveir® single-chamber leadless pacemaker for the treatment of patients in the U.S.Max stented tissue valve to treat people with slow heart rhythms.aortic regurgitation or stenosis.
The gross profit margin percentage was 50.750.5 percent for the thirdfirst quarter of 20222023 compared to 54.853.8 percent for the thirdfirst quarter of 2021.2022. The decrease in the first quarter of 2023 reflects the continuedunfavorable effects of lower sales of COVID-19 tests, foreign exchange, and higher costs for various manufacturing inputs, partially offset by the impact in 2022 of the voluntary product recall and Sturgis manufacturing stoppage in the Nutritional business during the first half of 2022 as well as the prioritization of infant formula sales related to the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). The decrease also reflects higher manufacturing and supply chain costs across Abbott's businesses, including inflation, commodities and distribution expenses as well as lower COVID-19 testing-related sales in 2022 and the nonrecurrence of a favorable change in estimate in the third quarter of 2021 related to a previously recognized restructuring plan.
The gross profit margin was 52.1 percent for the first nine months of 2022 compared to 51.6 percent for the first nine months of 2021. The increase reflects the nonrecurrence of 2021 restructuring charges and the impact in 2023 of higher sales of COVID-19 rapid tests during the first nine months of 2022. These favorable impacts were partially offset by the impact of the voluntary product recall and Sturgis manufacturing stoppage in the Nutritional business as well as higher manufacturing and supply chain costs across Abbott's businesses, including inflation and higher commodity and distribution expenses. The future extent to which inflation, supply chain disruptions, and unfavorable foreign exchange rates will have a material effect on Abbott's operating results is uncertain.gross margin improvement initiatives.
Research and development (R&D) expenses increased $110decreased $43 million, or 16.2 percent, in the third quarter of 2022 and increased $183 million, or 9.26.2 percent, in the first nine monthsquarter of 20222023 compared to the prior year. The increasedecrease in the third quarter primarily reflects the impairment of certain in-process R&D intangible assets in the third quarter of 2022. The increaseexpenses in the first nine monthsquarter of 2023 was alsoprimarily driven by higherthe timing of spending on various projects to advance products in development partially offset byand the favorable impact of foreign exchange.
Selling, general and administrative (SG&A) expenses decreased $36$25 million, or 1.30.9 percent, in the thirdfirst quarter of 20222023 compared to the prior year as higher selling and marketing spending to drive growth across various businesses was more than offset by the favorable impact of foreign exchange. SG&A expenses were virtually unchanged in the first nine months of 2022 compared to the prior year as higher sellingexchange and marketing spending was offset by the nonrecurrence of certain 2021 litigation costs and2022 expenses related to the favorable impact of foreign exchange.product recall in the Nutritional segment.
Other (Income) Expense, net
Other income, net increased from $74 million of income in the third quarter of 2021 to $93 million of income in the third quarter of 2022 and from $214$78 million of income in the first nine monthsquarter of 20212022 to $253$111 million of income in the first nine monthsquarter of 2022. The increases2023. The increase in the third quarter and the first nine monthsquarter of 2022 were primarily due to2023 reflects higher income in 20222023 related to the non-service cost components of net pension and post-retirement medical benefit costs. In the first nine months of 2022, the higher year-to-date income related to the non-service cost components was partially offset by the nonrecurrence of a gain on the sale of an equity method investment that occurred in the second quarter of 2021.
Interest Expense, net
Interest expense,expense, net declined $37decreased $65 million in the third quarter of 2022 and $61 million in the first nine monthsquarter of 2022 versus 20212023 due to the impact of higher interest rates and cash and short-term investment balances on interest income, and the repayment of debt in the first quarter of 2022 partially offset by the impact of interest rate hedge contracts related to certain fixed-rate debt.
Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first ninethree months of 20222023 and 2021,2022, taxes on earnings include approximately $36$3 million and $97$30 million, respectively, in excess tax benefits associated with share-based compensation. In the first ninethree months of 2023 and 2022, taxes on earnings also include approximately $20$22 million and $30 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.
Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $100$80 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.
Liquidity and Capital Resources September 30, 2022March 31, 2023 Compared with December 31, 20212022
The decrease in cash and cash equivalents from $9.8$9.9 billion at December 31, 20212022 to $9.6$9.2 billion at September 30, 2022March 31, 2023 primarily reflects share repurchases, the payment of dividends, share repurchases and capital expenditures, and the repayment of debt partially offset by the cash generated from operations in the first ninethree months of 2022.2023. Working capital was $11.5$9.8 billion at September 30, 2022March 31, 2023 and $11.1$9.7 billion at December 31, 2021.2022. The increase in working capital in 20222023 primarily reflects an increase in inventory and a decrease in accounts payable, partially offset by an increase in the current portion of long-term debt and a decrease in cash and cash equivalents.
In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first ninethree months of 20222023 totaled approximately $7.3$1.1 billion, which reflects a decrease of $211$922 million from the prior yearyear. The decrease is primarily due to an increased investmenta decline in working capitaloperating earnings, partially offset by higher operating earnings.the timing of the collection of trade receivables and a reduction in cash taxes paid. In the first three months of 2023, Net cash from operating activities includes $362$282 million of pension contributions and the payment of cash taxes of approximately $987 million in 2022.$122 million. In the first three months of 2022, Net cash from operating activities includes $366$334 million of pension contributions and the payment of cash taxes of approximately $990 million in 2021.$195 million.
On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.
In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. As of September 30, 2022,March 31, 2023, $2.15 billion of the $5 billion authorization remains available.
At September 30, 2022,March 31, 2023, Abbott’s long-term debt rating was AA- by Standard & Poor’s Corporation and A1 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2025.
In December 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott’s common shares from time to time. The new authorization was in addition to the $1.081 billion portion of the share repurchase program authorized in 2019 that was unused as of December 31, 2021.In the first nine monthsquarter of 2022,2023, Abbott repurchased 25.7approximately 3 million of its common shares for $2.965 billion which fully utilized the authorization remaining under the 2019 share repurchase program and a portion of the 2021 authorization.$300 million. As of September 30, 2022, $3.116March 31, 2023, $2.134 billion remains available for repurchase under the 2021share repurchase program.program authorized by the board of directors in December 2021.
In each of the first three quartersquarter of 2022,2023, Abbott declared a quarterly dividend of $0.47$0.51 per share on its common shares, which represents an increase of 4.48.5 percent over the $0.45$0.47 per share dividend declared in each of the first three quartersquarter of 2021.2022.
Business Acquisition
On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of approximately $850 million. The acquisition was funded with cash on hand. CSI sells an atherectomy system used in treating peripheral and coronary artery disease. The acquisition adds complementary technologies to Abbott’s portfolio of vascular device offerings. The transaction will be accounted for as a business combination.
Legislative Issues
Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 20212022 Annual Report on Form 10-K.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021,2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
PART I. FINANCIAL INFORMATION
Item 4. Controls and Procedures
(a)Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
(b)Changes in internal control over financial reporting. During the quarter ended September 30, 2022,March 31, 2023, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Abbott is involved in various claims, legal proceedings and investigations, asincluding those described in our Annual Report on Form 10-K for the year ended December 31, 2021 and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(c)Issuer Purchases of Equity Securities
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Period | | (a) Total Number of Shares (or Units) Purchased(1) | | (b) Average Price Paid per Share (or Unit) | | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs(2) | |
July 1, 2022 - July 31, 2022 | | — | | | $ | — | | | — | | | $ | 3,981,169,070 | | |
August 1, 2022 - August 31, 2022 | | 1,050,000 | | | 102.567 | | | 1,050,000 | | | 3,873,473,475 | | |
September 1, 2022 - September 30, 2022 | | 7,363,597 | | | 102.895 | | | 7,363,597 | | | 3,115,796,433 | | |
Total | | 8,413,597 | | | $ | 102.854 | | | 8,413,597 | | | $ | 3,115,796,433 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Period | | (a) Total Number of Shares (or Units) Purchased | | (b) Average Price Paid per Share (or Unit) | | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs | |
January 1, 2023 - January 31, 2023 | | — | | (1) | $ | — | | | — | | | $ | 2,434,092,348 | | (2) |
February 1, 2023 - February 28, 2023 | | 600,000 | | (1) | 100.933 | | | 600,000 | | | 2,373,532,278 | | (2) |
March 1, 2023 - March 31, 2023 | | 2,369,830 | | (1) | 101.037 | | | 2,369,830 | | | 2,134,092,391 | | (2) |
Total | | 2,969,830 | | (1) | 101.016 | | | 2,969,830 | | | $ | 2,134,092,391 | | (2) |
1.These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
2.On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.
Item 6. Exhibits
| | | | | | | | |
Exhibit No. | | Exhibit |
| | |
3.1 | | |
| | |
.10.1 | | |
| | |
31.1 | | |
| | |
31.2 | | |
| | |
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934. |
| | |
32.1 | | |
| | |
32.2 | | |
| | |
101 | | The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and nine months ended September 30, 2022,March 31, 2023, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements. |
| | |
104 | | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | |
ABBOTT LABORATORIES | |
| | |
By: | /s/ RobertROBERT E. Funck, Jr.FUNCK, JR. | |
| Robert E. Funck, Jr. | |
| Executive Vice President, Finance and Chief Financial Officer | |
| | |
| Date: November 1, 2022May 4, 2023 | |